APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urological Medications

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urological Medications Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchUrological Medications Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Urological Medications Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Urological Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urological Medications Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Urological Medications Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Urological Medications market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urological Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urological Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urological Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urological Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urological Medications market include Abbott, Novartis, Merck, Lilly, Pfizer, GlaxoSmithKline, AbbVie, Viatris and Sanofi-aventis U.S. LLC, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Urological Medications market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urological Medications and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urological Medications revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Urological Medications market.

Urological Medications Segment by Company

Abbott

Novartis

Merck

Lilly

Pfizer

GlaxoSmithKline

AbbVie

Viatris

Sanofi-aventis U.S. LLC

Piramal Pharma Solutions

Mallinckrodt

Endo International

Bayer HealthCare Pharmaceuticals

Astellas Pharma

ADVANZ PHARMA

Urological Medications Segment by Type

Anticholinergics

Alpha Blockers

5-Alpha Inhibitors

Others

Urological Medications Segment by Application

OAB

ED

Prostate Cancer

BPH

SUI

Others

Urological Medications Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Urological Medications status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Urological Medications key companies, revenue, market share, and recent developments.

3. To split the Urological Medications breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Urological Medications market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urological Medications significant trends, drivers, influence factors in global and regions.

6. To analyze Urological Medications competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urological Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urological Medications industry.

Chapter 3: Detailed analysis of Urological Medications company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Urological Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Urological Medications in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urological Medications Industry Trends Table 2. Urological Medications Industry Drivers Table 3. Urological Medications Industry Opportunities and Challenges Table 4. Urological Medications Industry Restraints Table 5. Global Urological Medications Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urological Medications Revenue Share by Company (2021-2026) Table 7. Global Urological Medications Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Urological Medications Key Company Manufacturing Base & Headquarters Table 9. Global Urological Medications Company, Product Type & Application Table 10. Global Urological Medications Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Urological Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anticholinergics Table 15. Significant Companies of Alpha Blockers Table 16. Significant Companies of 5-Alpha Inhibitors Table 17. Significant Companies of Others Table 18. Global Urological Medications Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Urological Medications Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Urological Medications Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Urological Medications Sales Value Share by Type (2021-2026) Table 22. Global Urological Medications Sales Value Share by Type (2027-2032) Table 23. Significant Companies of OAB Table 24. Significant Companies of ED Table 25. Significant Companies of Prostate Cancer Table 26. Significant Companies of BPH Table 27. Significant Companies of SUI Table 28. Significant Companies of Others Table 29. Global Urological Medications Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Urological Medications Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Urological Medications Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Urological Medications Sales Value Share by Application (2021-2026) Table 33. Global Urological Medications Sales Value Share by Application (2027-2032) Table 34. Global Urological Medications Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Urological Medications Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Urological Medications Sales Value Share by Region (2021-2026) Table 37. Global Urological Medications Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Urological Medications Sales Value Share by Region (2027-2032) Table 39. Global Urological Medications Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Urological Medications Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Urological Medications Sales Value Market Share by Country (2021-2026) Table 42. Global Urological Medications Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Urological Medications Sales Value Market Share by Country (2027-2032) Table 44. Abbott Company Information Table 45. Abbott Business Overview Table 46. Abbott Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Abbott Urological Medications Product Portfolio Table 48. Abbott Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Novartis Urological Medications Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Urological Medications Product Portfolio Table 58. Merck Recent Development Table 59. Lilly Company Information Table 60. Lilly Business Overview Table 61. Lilly Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Lilly Urological Medications Product Portfolio Table 63. Lilly Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer Urological Medications Product Portfolio Table 68. Pfizer Recent Development Table 69. GlaxoSmithKline Company Information Table 70. GlaxoSmithKline Business Overview Table 71. GlaxoSmithKline Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GlaxoSmithKline Urological Medications Product Portfolio Table 73. GlaxoSmithKline Recent Development Table 74. AbbVie Company Information Table 75. AbbVie Business Overview Table 76. AbbVie Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. AbbVie Urological Medications Product Portfolio Table 78. AbbVie Recent Development Table 79. Viatris Company Information Table 80. Viatris Business Overview Table 81. Viatris Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Viatris Urological Medications Product Portfolio Table 83. Viatris Recent Development Table 84. Sanofi-aventis U.S. LLC Company Information Table 85. Sanofi-aventis U.S. LLC Business Overview Table 86. Sanofi-aventis U.S. LLC Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sanofi-aventis U.S. LLC Urological Medications Product Portfolio Table 88. Sanofi-aventis U.S. LLC Recent Development Table 89. Piramal Pharma Solutions Company Information Table 90. Piramal Pharma Solutions Business Overview Table 91. Piramal Pharma Solutions Urological Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Piramal Pharma Solutions Urological Medications Product Portfolio Table 93. Piramal Pharma Solutions Recent Development Table 94. Mallinckrodt Company Information Table 95. Mallinckrodt Business Overview Table 96. Mallinckrodt Urological Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Mallinckrodt Urological Medications Product Portfolio Table 98. Mallinckrodt Recent Development Table 99. Endo International Company Information Table 100. Endo International Business Overview Table 101. Endo International Urological Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Endo International Urological Medications Product Portfolio Table 103. Endo International Recent Development Table 104. Bayer HealthCare Pharmaceuticals Company Information Table 105. Bayer HealthCare Pharmaceuticals Business Overview Table 106. Bayer HealthCare Pharmaceuticals Urological Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio Table 108. Bayer HealthCare Pharmaceuticals Recent Development Table 109. Astellas Pharma Company Information Table 110. Astellas Pharma Business Overview Table 111. Astellas Pharma Urological Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Astellas Pharma Urological Medications Product Portfolio Table 113. Astellas Pharma Recent Development Table 114. ADVANZ PHARMA Company Information Table 115. ADVANZ PHARMA Business Overview Table 116. ADVANZ PHARMA Urological Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. ADVANZ PHARMA Urological Medications Product Portfolio Table 118. ADVANZ PHARMA Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Urological Medications Product Image Figure 2. Global Urological Medications Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urological Medications Market Size (2021-2032) & (US$ Million) Figure 4. Global Urological Medications Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anticholinergics Image Figure 8. Alpha Blockers Image Figure 9. 5-Alpha Inhibitors Image Figure 10. Others Image Figure 11. Global Urological Medications Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Urological Medications Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Urological Medications Sales Value Share by Type (2021-2032) Figure 14. OAB Image Figure 15. ED Image Figure 16. Prostate Cancer Image Figure 17. BPH Image Figure 18. SUI Image Figure 19. Others Image Figure 20. Global Urological Medications Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Urological Medications Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Urological Medications Sales Value Share by Application (2021-2032) Figure 23. Global Urological Medications Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Urological Medications Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Urological Medications Sales Value (2021-2032) & (US$ Million) Figure 26. North America Urological Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Urological Medications Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Urological Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Urological Medications Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Urological Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Urological Medications Sales Value (2021-2032) & (US$ Million) Figure 32. South America Urological Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Urological Medications Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Urological Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Urological Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Urological Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Urological Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergics
  • Alpha Blockers
  • 5-Alpha Inhibitors
  • Others
Applications
  • OAB
  • ED
  • Prostate Cancer
  • BPH
  • SUI
  • Others
Companies covered
  • Abbott
  • Novartis
  • Merck
  • Lilly
  • Pfizer
  • GlaxoSmithKline
  • AbbVie
  • Viatris
  • Sanofi-aventis U.S. LLC
  • Piramal Pharma Solutions
  • Mallinckrodt
  • Endo International
  • Bayer HealthCare Pharmaceuticals
  • Astellas Pharma
  • ADVANZ PHARMA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Urological Medications Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Urological Medications Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Urological Medications Market Dynamics
  1. 2.1 Urological Medications Industry Trends
  2. 2.2 Urological Medications Industry Drivers
  3. 2.3 Urological Medications Industry Opportunities and Challenges
  4. 2.4 Urological Medications Industry Restraints
3 Urological Medications Market by Company
  1. 3.1 Global Urological Medications Company Revenue Ranking in 2025
  2. 3.2 Global Urological Medications Revenue by Company (2021-2026)
  3. 3.3 Global Urological Medications Company Ranking (2024-2026)
  4. 3.4 Global Urological Medications Company Manufacturing Base and Headquarters
  5. 3.5 Global Urological Medications Company Product Type and Application
  6. 3.6 Global Urological Medications Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Urological Medications Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Urological Medications Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Urological Medications Market by Type
  1. 4.1 Urological Medications Type Introduction
  2. 4.1.1 Anticholinergics
  3. 4.1.2 Alpha Blockers
  4. 4.1.3 5-Alpha Inhibitors
  5. 4.1.4 Others
  6. 4.2 Global Urological Medications Sales Value by Type
  7. 4.2.1 Global Urological Medications Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Urological Medications Sales Value by Type (2021-2032)
  9. 4.2.3 Global Urological Medications Sales Value Share by Type (2021-2032)
5 Urological Medications Market by Application
  1. 5.1 Urological Medications Application Introduction
  2. 5.1.1 OAB
  3. 5.1.2 ED
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 BPH
  6. 5.1.5 SUI
  7. 5.1.6 Others
  8. 5.2 Global Urological Medications Sales Value by Application
  9. 5.2.1 Global Urological Medications Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Urological Medications Sales Value by Application (2021-2032)
  11. 5.2.3 Global Urological Medications Sales Value Share by Application (2021-2032)
6 Urological Medications Regional Value Analysis
  1. 6.1 Global Urological Medications Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urological Medications Sales Value by Region (2021-2032)
  3. 6.2.1 Global Urological Medications Sales Value by Region: 2021-2026
  4. 6.2.2 Global Urological Medications Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Urological Medications Sales Value (2021-2032)
  7. 6.3.2 North America Urological Medications Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Urological Medications Sales Value (2021-2032)
  10. 6.4.2 Europe Urological Medications Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Urological Medications Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Urological Medications Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Urological Medications Sales Value (2021-2032)
  16. 6.6.2 South America Urological Medications Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Urological Medications Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Urological Medications Sales Value Share by Country, 2025 VS 2032
7 Urological Medications Country-level Value Analysis
  1. 7.1 Global Urological Medications Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urological Medications Sales Value by Country (2021-2032)
  3. 7.2.1 Global Urological Medications Sales Value by Country (2021-2026)
  4. 7.2.2 Global Urological Medications Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Urological Medications Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Urological Medications Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Urological Medications Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Urological Medications Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Urological Medications Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Urological Medications Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Urological Medications Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Urological Medications Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Urological Medications Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Urological Medications Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Urological Medications Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Urological Medications Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Urological Medications Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Urological Medications Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Urological Medications Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Urological Medications Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Urological Medications Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Urological Medications Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Urological Medications Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Urological Medications Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Urological Medications Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Urological Medications Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Urological Medications Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Urological Medications Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Urological Medications Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Urological Medications Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Urological Medications Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Urological Medications Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Urological Medications Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Urological Medications Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Urological Medications Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Urological Medications Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Urological Medications Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Urological Medications Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Urological Medications Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Urological Medications Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Urological Medications Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Urological Medications Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Urological Medications Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Urological Medications Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Urological Medications Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Urological Medications Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Urological Medications Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Urological Medications Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Urological Medications Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Urological Medications Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Urological Medications Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Urological Medications Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Urological Medications Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Urological Medications Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Urological Medications Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Urological Medications Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Urological Medications Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Urological Medications Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Urological Medications Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Urological Medications Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Urological Medications Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Urological Medications Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Urological Medications Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Urological Medications Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Urological Medications Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Urological Medications Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Urological Medications Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Urological Medications Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Urological Medications Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Urological Medications Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Urological Medications Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Urological Medications Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Urological Medications Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Urological Medications Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Urological Medications Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Urological Medications Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Urological Medications Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Urological Medications Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Urological Medications Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Urological Medications Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Urological Medications Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Urological Medications Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Urological Medications Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Urological Medications Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Urological Medications Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Urological Medications Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Urological Medications Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Urological Medications Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Urological Medications Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Urological Medications Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Urological Medications Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Urological Medications Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Urological Medications Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Urological Medications Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Lilly
  20. 8.4.1 Lilly Company Information
  21. 8.4.2 Lilly Business Overview
  22. 8.4.3 Lilly Urological Medications Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lilly Urological Medications Product Portfolio
  24. 8.4.5 Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Urological Medications Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Urological Medications Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Urological Medications Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Urological Medications Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Urological Medications Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Urological Medications Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Urological Medications Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Urological Medications Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Sanofi-aventis U.S. LLC
  50. 8.9.1 Sanofi-aventis U.S. LLC Company Information
  51. 8.9.2 Sanofi-aventis U.S. LLC Business Overview
  52. 8.9.3 Sanofi-aventis U.S. LLC Urological Medications Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi-aventis U.S. LLC Urological Medications Product Portfolio
  54. 8.9.5 Sanofi-aventis U.S. LLC Recent Developments
  55. 8.10 Piramal Pharma Solutions
  56. 8.10.1 Piramal Pharma Solutions Company Information
  57. 8.10.2 Piramal Pharma Solutions Business Overview
  58. 8.10.3 Piramal Pharma Solutions Urological Medications Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Piramal Pharma Solutions Urological Medications Product Portfolio
  60. 8.10.5 Piramal Pharma Solutions Recent Developments
  61. 8.11 Mallinckrodt
  62. 8.11.1 Mallinckrodt Company Information
  63. 8.11.2 Mallinckrodt Business Overview
  64. 8.11.3 Mallinckrodt Urological Medications Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Mallinckrodt Urological Medications Product Portfolio
  66. 8.11.5 Mallinckrodt Recent Developments
  67. 8.12 Endo International
  68. 8.12.1 Endo International Company Information
  69. 8.12.2 Endo International Business Overview
  70. 8.12.3 Endo International Urological Medications Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Endo International Urological Medications Product Portfolio
  72. 8.12.5 Endo International Recent Developments
  73. 8.13 Bayer HealthCare Pharmaceuticals
  74. 8.13.1 Bayer HealthCare Pharmaceuticals Company Information
  75. 8.13.2 Bayer HealthCare Pharmaceuticals Business Overview
  76. 8.13.3 Bayer HealthCare Pharmaceuticals Urological Medications Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio
  78. 8.13.5 Bayer HealthCare Pharmaceuticals Recent Developments
  79. 8.14 Astellas Pharma
  80. 8.14.1 Astellas Pharma Company Information
  81. 8.14.2 Astellas Pharma Business Overview
  82. 8.14.3 Astellas Pharma Urological Medications Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Astellas Pharma Urological Medications Product Portfolio
  84. 8.14.5 Astellas Pharma Recent Developments
  85. 8.15 ADVANZ PHARMA
  86. 8.15.1 ADVANZ PHARMA Company Information
  87. 8.15.2 ADVANZ PHARMA Business Overview
  88. 8.15.3 ADVANZ PHARMA Urological Medications Revenue and Gross Margin (2021-2026)
  89. 8.15.4 ADVANZ PHARMA Urological Medications Product Portfolio
  90. 8.15.5 ADVANZ PHARMA Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst